Market Place
Sourcing Support
Vivos & Cellev8 Collaborate to Address Sleep Apnea & Stress
10 Dec 2024 //
ACCESSWIRE
Vivos Therapeutics Reports Q3 2024 Financial Results & Update
14 Nov 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Release of Q3 2024 Financial Results & Conf Call
13 Nov 2024 //
GLOBENEWSWIRE
Vivos Inc. Certifies New Clinic For IsoPet® Therapy
18 Oct 2024 //
GLOBENEWSWIRE
Vivos Granted CPT Codes For CARE Oral Medical Devices
08 Oct 2024 //
GLOBENEWSWIRE
Vivos Inc. Extends IsoPet Therapy To Exotic Animals
30 Sep 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Announces Pricing Of $4.3 Million Offering
19 Sep 2024 //
GLOBENEWSWIRE
Vivos Gets FDA Clearance For Pediatric Sleep Apnea Device
18 Sep 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Schedules Q2 2024 Financial Results And Conference Call
14 Aug 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Reports Q2 2024 Financial Results And Operational Update
14 Aug 2024 //
GLOBENEWSWIRE
Vivos Submits FDA Application To Initiate Human Clinical Trials
28 Jun 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot
27 Jun 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Closes $7.5M Investment, Launches Alliance
12 Jun 2024 //
GLOBENEWSWIRE
Vivos Schedules Q1 2024 Results Release, Conference Call
14 May 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Reports Q1 2024 Results, Operational Update
14 May 2024 //
GLOBENEWSWIRE
Vivos` CARE devices approved for Medicare.
09 Apr 2024 //
GLOBENEWSWIRE
Vivos Schedules Release of Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million
15 Feb 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Highlights Significant Favorable Market Developments
06 Feb 2024 //
GLOBENEWSWIRE
Vivos Therapeutics Sees Positive Preliminary Metrics
08 Jan 2024 //
GLOBENEWSWIRE
Radiogel Radionuclide Therapy Receives FDA Breakthrough Device Designation
20 Dec 2023 //
GLOBENEWSWIRE
Vivos Presents Groundbreaking Event: œEmpowering Women to Champion Airway
11 Dec 2023 //
GLOBENEWSWIRE
Vivos Receives First Ever FDA 510(k) Clearance for Oral Device Treatment
30 Nov 2023 //
YAHOO FINANCE
Vivos Therapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Closes $4 Million Private Placement
02 Nov 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Announces Pricing of $4 Million Private Placement
31 Oct 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Announces Reverse Stock Split
26 Oct 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare
24 Oct 2023 //
GLOBENEWSWIRE
Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine
11 Oct 2023 //
GLOBENEWSWIRE
Vivos Announces Collaboration in the Middle East-North Africa Region
05 Oct 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Executes Strategic Agreements with Ormco
04 Oct 2023 //
GLOBENEWSWIRE
Vivos Reschedules Second Quarter 2023 Financial Results Conference Call
16 Aug 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Reports Second Quarter 2023 Financial Results
16 Aug 2023 //
GLOBENEWSWIRE
Vivos to Reschedule Second Quarter 2023 Financial Results Conference Call
14 Aug 2023 //
GLOBENEWSWIRE
Vivos Schedules Release of Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Vivos Announces Certification of Three New IsoPet Precision Radionuclide Therapy
07 Aug 2023 //
GLOBENEWSWIRE
Vivos Schedules Release of First Quarter 2023 Financial Results
06 Jun 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Announces Additional Strategic Cash Flow Positive Operations
09 May 2023 //
GLOBENEWSWIRE
Clinical Study Shows 92% of Patients Report Resolution of Migraine Vivos’ POD
01 May 2023 //
BIOSPACE
Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches
01 May 2023 //
GLOBENEWSWIRE
Vivos Schedules Release of 4Q and Full Reports Full 2022 FYR and Conference Call
30 Mar 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Reports 4Q and Full Reports Full 2022 FYR
30 Mar 2023 //
GLOBENEWSWIRE
Vivos to Participate in Fireside Chat at the 35th Annual ROTH Conference
08 Mar 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition
01 Mar 2023 //
GLOBENEWSWIRE
Vivos to Present at the Emerging Growth Conference on February 22, 2023
21 Feb 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements
20 Jan 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Closes $8 Million Private Placement
09 Jan 2023 //
GLOBENEWSWIRE
Vivos Therapeutics Announces Pricing of $8 Million Private Placement
05 Jan 2023 //
GLOBENEWSWIRE
Vivos Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance
04 Jan 2023 //
GLOBENEWSWIRE
Vivos Schedules Release of Second and Third Quarter 2022 Financial Results
16 Dec 2022 //
GLOBENEWSWIRE
Vivos Announces Revenue Stream Through Strategic Medical Billing Relationship
15 Dec 2022 //
GLOBENEWSWIRE
Vivos Announces Receipt of Notice from Nasdaq Regarding Late Filing of Q3 2022
28 Nov 2022 //
GLOBENEWSWIRE
Vivos Therapeutics Provides Update on Revenue Recognition Review
22 Nov 2022 //
GLOBENEWSWIRE
Vivos received Notice from Nasdaq Regarding Late Filing of Report on Form 10-Q
26 Aug 2022 //
GLOBENEWSWIRE
No Q2 call yet for Vivos; San Diego biotech collabs with MD Anderson
23 Aug 2022 //
ENDPTS
Vivos Therapeutics Provides Update on Second Quarter Earnings Delay
22 Aug 2022 //
GLOBENEWSWIRE
Vivos to Reschedule Second Quarter 2022 Financial Results Conference Call
15 Aug 2022 //
GLOBENEWSWIRE
Vivos Therapeutics Schedules Q2 2022 Financial Results Conference Call
09 Aug 2022 //
GLOBENEWSWIRE
